Ongoing Clinical Trials

Share:

If you would like more information about one of the studies below please e-mail deneva.zamora@houstonretina.com, call 713-524-3434 or contact the study specific coordinator.


Wet Age-Related Macular Degeneration Trials


ALLERGAN CEDAR

A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

For additional information on this trial, click here

Study Coordinator (Texas Medical Center): Chelsey Moore, chelsey.moore@houstonretina.com
Study Coordinator (Woodlands): Stacy Supapo, stacy.supapo@houstonretina.com


ALCON RTH258-C001 (HAWK)

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age Related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, cassandra.cone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegramelisa.bocanegra@houstonretina.com 


REGENERON 1417 (CAPELLA)

A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, ccone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


T-REX AMD

A Phase IIIb, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.5mg Ranibizumab Given Monthly Compared to a Treat and Extend Protocol in Patients With Wet Age-related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center & Katy): Cassie Cone, ccone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


OPTHOTECH 1003 (ECLIPSE) 

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, cassandra.cone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


OPTHOTECH 1006

An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer

For additional information on this trial, click here.

Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


ICONIC (EMERGE)

Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration

For additional information on this trial, click here

Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


ROCHE BP29647 (AVENUE) 

A Proof-of-Concept Study of RG7716 in Participants with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

For additional information on this trial, click here

Study Coordinator (Texas Medical Center): Cassie Cone, cassandra.cone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


X82-OPH-201 (TYROGENEX)

A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea® compared to prn Eylea® mono therapy in neovascular AMD

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): JoLene Carranza, jolene.carranza@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


OHR-1601 (MAKO)

Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration

For additional information on this trial, click here

Study Coordinator (Texas Medical Center & Katy): Chelsey Moore, chelsey.moore@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com
Study Coordinator (Kingwood): Cassie Cone, cassandra.cone@houstonretina.com


REGENERON 1517 (ONYX) 

A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration

For additional information on this trial, click here

Study Coordinator (Texas Medical Center): Rebecca Yeerebecca.yee@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


Geographic Atrophy Trials


GX29185 (Spectri)

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, cassandra.cone@houstonretina.com

Study Coordinator (Woodlands): Cassie Cone, cassandra.cone@houstonretina.com

 


 

APELLIS POT-CP121614 (FILLY)


A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, ccone@houstonretina.com

Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com

 


 

GX29639 (PROXIMA B)

 

A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary To Age-Related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, cassandra.cone@houstonretina.com
Study Coordinator (Woodlands): Stacy Supapo, stacy.supapo@houstonretina.com


PRO-CON 

A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as Prophylaxis against Conversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, cassandra.cone@houstonretina.com


PROXIMA A

An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Cassie Cone, cassie.cone@houstonretina.com

Study Coordinator (Woodlands): Stacy Supapo, stacy.supapo@houstonretina.com

 


 

ROCHE BP30099 (BOULEVARD)

A Multiple-Center, Multiple-Dose, Randomized, Active Comparator−Controlled, Double-Masked, Parallel Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): JoLene Caranza, jolene.carranza@houstonretina.com
Study Coordinator (Woodlands): Stacy Supapostacy.supapo@houstonretina.com


SCIFLUOR

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): JoLene Carranza, jolene.carranza@houstonretina.com


DRCR V

Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

For additional information on this trial, click here.

Study Coordinator (Medical Center): Amy Hutson, amy.hutson@houstonretina.com
Study Coordinator (Woodlands):  Stacy Supapo, stacy.supapo@houstonretina.com


DRCR U 

Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Phakic & Pseudophakic Eyes

For additional information on this trial, click here.

Study Coordinator (Medical Center): Amy Hutson, amy.hutson@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


REGENERON 1518 (RUBY)

Anti-vascular Endothelial Growth Factor plus Anti-angiopoietin 2 in Fixed combination therapy: Evaluation for the Treatment of Diabetic Macular Edema

For additional information on this trial, click here.

Study Coordinator (Medical Center): JoLene Caranza, jolene.carranza@houstonretina.com
Study Coordinator (Woodlands): Stacy Supapostacy.supapo@houstonretina.com


T-REX DME 

A Phase I/II, Open Label, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.3 mg Ranibizumab Given Monthly Compared to a Treat and Extend Protocol in Patients With Diabetic Macular Edema

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center & Katy): Cassie Cone, ccone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


DAVE 

A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.5mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.5mg Ranibizumab 4 Months Monotherapy, Then as Needed-DME-AntiVEgf

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center & Katy): Cassie Cone, ccone@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


ENDURANCE 1

Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center & Katy): JoLene Carranza, jolene.carranza@houstonretina.com
Study Coordinator (Woodlands): Melisa Bocanegra, melisa.bocanegra@houstonretina.com


DRCR AA 

Peripheral DR Lesions on Ultrawide-field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time

Study Coordinator (Texas Medical Center): Amy Hutson, amy.hutson@houstonretina.com
Study Coordinator (Woodlands): Stacy Supapo, stacy.supapo@houstonretina.com


Proliferative Diabetic Retinopathy Trials


DRCR S 

Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Amy Hutson, amy.hutson@houstonretina.com
Study Coordinator (Woodlands): Stacy Supapo, stacy.supapo@houstonretina.com


Uveitis Trials


NOVARITS CLFG316A2204

Safety, Tolerability and Efficacy of Intravitreal LFG316 in Patients with Multifocal Choroiditis and Panuveitis (MCP)

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Chelsey Moore, chelsey.moore@houstonretina.com


MUST

Multicenter Uveitis Steroid Treatment Trial

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Chelsey Moore, chelsey.moore@houstonretina.com


PSV-FAI-001 (PSIVIDA)

A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

For additional information on this trial, click here.

Study Coordinator (Texas Medical Center): Chelsey Moore chelsey.moore@houstonretina.com